期刊文献+

玫瑰痤疮发病因素调查及其紫外线最小红斑量测定 被引量:12

The Investigation of Rosacea Etiology and Assessement of its Minimal Erythema Dose in Response to UV
下载PDF
导出
摘要 目的探讨玫瑰痤疮的发病因素及其紫外线最小红斑量检测。方法制定针对玫瑰痤疮发病因素的调查表,对收集的98例玫瑰痤疮患者调查表进行统计学分析;根据患者病情对其中42例进行紫外线最小红斑量检测。结果玫瑰痤疮的发病与多种因素相关,如辛辣刺激食物、精神因素、温度变化、外用药物、系统性疾病,29例(29.59%)患者有家族遗传史,其中检测的42例中34例(80.95%)患者紫外线最小红斑量值低于正常,中波紫外线最小红斑量值(ultravioletB—minimalethemadose,UVB—MED),为7.70和15.70mJ/em。,长波紫外线最小红斑量值(ultravioletA—minimalethemadose,UVA—MED)为(11.10±4.77)J/em‘(5.40~18.20J/cm2),而且与UVB—MED相比,UVA—MED及(UVA+UVB)MED敏感的患者更易诱发病情加重,差异有统计学意义(P〈0.001;P〈0.01)。结论玫瑰痤疮的发病和许多因素有关,其中紫外线照射(特别是UVA)是很重要的诱因。 Objective To explore the incidence and risk factors of rosacea, and detect the minimal erythema dose (MED) to assess its sensitivity to Ultraviolet(UV) light. Metheds Ninety-eight patients with rosacea were recruited and questionnaire& Results According to our study, the pathogenesis of rosacea were related to many factors, such as hot and spicy food, psychological factors, temperature changes, topical medications, systemic disease, and 29(29.59% ) patients with family history. Among the 42 patients undergoing MED test, 54 patients(80.95% ) with rosacea were sensitive to UV:UVB-MED value were 7.70 and 15.70mJ/cm2, UVA-MED value was ( 11.10 + 4.77 ) J/cmz ( range, 5.40 ~ 18.20mJ/cm~ ). Moreover, heating environment exposure can aggravate the disease. The UVA sensitive and UVA-UVB double sensitive patients were with higher risks of rosacea than the UVA sensitive patients( P 〈 0. 001 ;P 〈 0.01 ). Conclusion There are many factors relate to rosacea, and UV irradiation especially UVA is one of the important factor.
出处 《中国皮肤性病学杂志》 CAS 北大核心 2013年第12期1233-1235,共3页 The Chinese Journal of Dermatovenereology
关键词 玫瑰痤疮 紫外线 最小红斑量 发病因素 Rosacea Ultraviolet Minimal ethema dose Pathogenesis
  • 相关文献

参考文献10

  • 1马一平,林麟.酒渣鼻研究进展[J].国际皮肤性病学杂志,2010,36(1):56-58. 被引量:6
  • 2Fuller D,Martin S. Rosacea[ J]. J Midwifery Womens Health,2012 ,57(4) :403 -409.
  • 3Biniek K, Levi K, Dauskardt RH. Solar UV radiation reduces the barrierfunction of human skin[ J]. Proc Natl Acad Sci USA,2012 ,109 (42):17111 -17116.
  • 4蔄茂强,Peter M Elias.紫外线照射对表皮通透屏障功能的影响及其意义[J].中华皮肤科杂志,2010,43(12):889-891. 被引量:5
  • 5Yamasaki K, Kanada K, Macleod DT, et al. TLR2 expression is in- creased in rosacca and stimulates enhanced serine proteasc production by keratinocytes [ Jl. J Invest Dermatol,2011,131 ( 3 ) :688 - 697.
  • 6Gerber PA, Buhren BA, Steinhoff M, et al. Rosacea: The cytokine andchemokine network[ J]. J Investig Dermatol Symp Proc ,2011 ,15(1 ):40 -47.
  • 7Yamasaki K, Gallo RL. Rosacea as a disease of cathelicidins and skininnate immunity [J] . J Investig Dermatol Symp Proc ,2011,15( 1) :12 - 15.
  • 8Shibata M, Katsuyama M, Onodera T, et al. Glucocorticoids enhanceToll-like receptor 2 expression in human keratinocytes stimulated withPropionibacterium acnes or proinflammatory cytokines[ J] . J Invest Der-matol, 2009,129 (2 ) :375 -382.
  • 9Debacq-Chainiaux F, Leduc C, Verbeke A, et al. UV, stress and aging[J]. Dermatoendocrinol,2012,4(3 ) :236 -240.
  • 10Lim TG, Jung SK, Kim JE, et al. NADPH oxidase is a novel target ofdelphinidin for the inhibition of UVB-induced MMP-1 expression inhuman dermal fibroblasts[ J]. Exp Dermatol,2013 ,22(6) :428 -430.

二级参考文献54

  • 1Buechner SA. Rosacea: An Update. Dermatology, 2005, 210(2): 100-108.
  • 2Wilkin J, Dalai M, Detmar M, et al. Standard classification of rosacea: Report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol, 2002, 46(4): 584-587.
  • 3Crawford G, Pelle M, James W. Rosacea. I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol, 2004, 51 (3): 327-341.
  • 4Wilkin J, Dahl M, Detmar M, et al. Standard grading system for rosacea: Report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol, 2004, 50( 6 ): 907-912.
  • 5PeUe MT, Crawford GH, James WD. Rosacea: II. Therapy. J Am Acad Dermatol, 2004, 51(4): 499-512.
  • 6Gollnick H, Layton A. Azelaic acid 15% gel in the treatment of rosacea. Expert Opin Pharmacother, 2008, 9( 15 ): 2699-2706.
  • 7Thiboutot D, Thieroff-Ekerdt R, Graupe K. Efficacy and safety of azelaic acid (15%) gel as a new reatment for papulopustular rosacea:Results from two vehicle-controlled, randomized phase IIl studies. J Am Acad Dermatol, 2003, 48(6): 836-845.
  • 8Wolf JE Jr, Kerrouche N, Arsonnaud S. Efficacy and safety of once-daily metronidazole 1% gel compared with twice-daily azelaic acid 15% gel in the treatment of rosacea. Cutis, 2006, 77 (4): 3-11.
  • 9Thiboutot DM, Fleischer AB, Del Rosso JQ, et al. Azelaic acid 15% gel once daily versus twice daily in papulopustular rosacea. J Drugs Dermatol, 2008, 7(6): 541-546.
  • 10Del Rosso J. Evaluating the role of topical therapies in the management of rosacea: Focus on combination sodium sulfacetamide and sulfur formulations. Cutis, 2004, 73( 1 ): 29-33.

共引文献9

同被引文献120

引证文献12

二级引证文献103

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部